


Abstract

The invention relates to a novel anilide compound and a pharmaceutical composition comprising the same. The invention relates to a compound represented by the following general formula:



wherein



represents a divalent residue of benzene with a substituent(s), heterocycle-condensed benzene which may or may not have a substituent, pyridine which may or may not have a substituent, cyclohexane or naphthalene
or



Ar represents an aryl group which may or may not have a substituent;

X represents -NH-, oxygen atom or sulfur atom;

Y represents -NR₁-, oxygen atom, sulfur atom, sulfoxide or sulfone;

Z represents single bond or -NR₅-;

R₄ represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent;

R₅ represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; and

n represents an integer of 0 to 15.

The inventive compounds are useful in the form of pharmaceutical composition, specifically as acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor.